Related Experiment Video
Updated: Oct 29, 2025
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
9.9K
Health equality, race and pharmacogenomics
Emma F Magavern1, Deepti Gurdasani1, Fu L Ng2
1William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
British Journal of Clinical Pharmacology
|July 12, 2021
Summary
Pharmacogenomics research must include diverse populations to prevent health disparities. Addressing diversity in pharmacogenomics ensures equitable healthcare improvements for everyone.
Area of Science:
- Pharmacogenomics
- Genetics
- Clinical Practice
Background:
- Pharmacogenomics is transitioning into routine clinical use.
- Historical and social factors, including population stratification, impact healthcare equity.
- Ensuring diverse representation in research is crucial for equitable outcomes.
Purpose of the Study:
- To critically review the role of diversity in pharmacogenomics.
- To identify potential pitfalls in the implementation of pharmacogenomics.
- To raise awareness among healthcare providers regarding diversity in pharmacogenomics.
Main Methods:
- Literature review of current pharmacogenomics research and implementation.
- Critical analysis of diversity inclusion in pharmacogenomic studies.
- Examination of evidence gaps and potential negative consequences.
Main Results:
- Pharmacogenomics implementation requires careful consideration of diverse populations.
- Population stratification can exacerbate health disparities if not managed properly.
- Significant evidence gaps exist regarding diversity in pharmacogenomics.
Conclusions:
- Promoting health equality in pharmacogenomics necessitates addressing diversity.
- Strategies are needed to minimize negative consequences and promote equitable healthcare.
- Increased prescriber awareness is vital for responsible pharmacogenomics integration.
Related Concept Videos
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
37
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
37
01:15Drug Dosing: Geriatric Patients
52
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
52
01:21Drug Dosing: Obese Patients
36
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
36
01:24Dosage Regimen: Individualization
29
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
29
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
57
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
57
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
42
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
42